Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 27;12(4):e0175562.
doi: 10.1371/journal.pone.0175562. eCollection 2017.

Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan

Yuely A Capileno  1 , Rafael Van den Bergh  1 , Dmytro Donchunk  1 , Sven Gudmund Hinderaker  2   3 , Saeed Hamid  4 , Rosa Auat  1 , Gul Ghuttai Khalid  1 , Razia Fatima  2   5 , Aashifa Yaqoob  5 , Catherine Van Overloop  1
Affiliations

Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan

Yuely A Capileno et al. PLoS One. .

Erratum in

Abstract

Background: The burden of hepatitis C (HCV) infection in Pakistan is among the highest in the world, with a reported national HCV prevalence of 6.7% in 2014. In specific populations, such as in urban communities in Karachi, the prevalence is suspected to be higher. Interferon-free treatment for chronic HCV infection (CHC) could allow scale up, simplification and decentralization of treatment to such communities. We present an interim analysis over the course of February-December 2015 of an interferon-free, decentralised CHC programme in the community clinic in Machar Colony, Karachi, Pakistan.

Design: A retrospective analysis of a treatment cohort.

Results: There were 1,089 patients included in this analysis. Aspartate to platelet ratio index score was used to prioritize patients in terms of treatment initiation, with 242 patients placed in high priority for treatment and 202 starting treatment as scheduled. 169 patients started HCV treatment with Sofosbuvir-Ribavirin regimen according to HCV genotype over the course of 2015: of these, 35% had Hemoglobin reductions below 11.0 g/dl during the treatment course. Among the 153 patients (85%) with genotype 3 HCV infection, 84% of patients achieved sustained virologic response at 12 weeks following treatment completion (SVR 12).

Conclusion: Outcomes of HCV treatment with all oral combination in an integrated, decentralized model of care for CHC in a primary care setting, using simplified diagnostic and treatment algorithms, are comparable to the outcomes achieved in clinical trial settings for Sofosbuvir-based regimens. Our results suggest the feasibility and the pertinence if including interferon-free treatment regimens in the national programme, at both provincial and national levels.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flowchart for diagnosis and treatment prioritization among CHC patients in a primary health care-based program for management of chronic Hepatitis C, Karachi, Pakistan; February to December 2015.
1 Initial clinical assessment rules out patients with known medical conditions contraindicated for treatment initiation such as decompensated cirrhosis, hematologic diseases, severe renal insufficency. 2Aspartate aminotransferase (AST) to Platelet Ratio Index 3Patients with low APRI scores (0.1–0.49), with co-infection (TB, HIV, and Hepatitis B), Pregnancy and Lactation 4Patients with APRI score 0.5–0.99 5Patients with APRI above 1.0
Fig 2
Fig 2. Flowchart for treatment among chronic Hepatitis C patients in a primary health care-based program for management of chronic Hepatitis C, Karachi, Pakistan; February to December 2015.
1 Sofosbuvir 400mg/day + weight-based Ribavirin 800–1200 mg/day + Pegylated interferon 180 μg/week Subcutaneous for 12 weeks 2 Sofosbuvir 400 mg/day +weight based Ribavirin 800–1200 mg/day 3 Sustained virological response (cure)
Fig 3
Fig 3. Percentage of chronic Hepatitis C patients who developed anemia while on treatment in a primary health care-based program for management of chronic Hepatitis C, Karachi, Pakistan; February to December 2015.
1 WHO. Hemoglobin concentrations for the diagnosis of anemia and assessment of severity.
See this image and copyright information in PMC

References

    1. World Health Organization. Guidelines for the screening, care and treatment of persons with Hepatitis C infection. Geneva (CH); WHO; 2014. 122 p - PubMed
    1. Hanafiah K, Groeger J, Flaxman A, Wiersma S. Global Epidemiology of Hepatitis C Virus Infection: New Estimates of Age-Specific Antibody to HCV Seroprevalence. Hepatology. 2013; 57 (4): 1333–1342 10.1002/hep.26141 - DOI - PubMed
    1. Mohamoud YA, Riome S, Abu Raddad LJ; Epidemiology of the Hepatitis C virus in the Arabian Gulf countries: systematic review and meta-analysis of prevalence. International Journal of Infectious Disease. 2016; 10.1016/j.ijid.2016.03.012 - DOI - PubMed
    1. Ali SA, Donabue R, Qureshi H, Vermund S. Hepatitis B and Hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 2009; 13 (1): 9–19 10.1016/j.ijid.2008.06.019 - DOI - PMC - PubMed
    1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global Epidemiology and genotype distribution of the Hepatitis C virus infection. J Hepatol 2014; 61: S45–S57 10.1016/j.jhep.2014.07.027 - DOI - PubMed

LinkOut - more resources